Metronomic chemotherapy as a palliative treatment in poor performance status patients with advanced epithelial ovarian carcinoma

The Chinese-German Journal of Clinical Oncology 09/2011; 10(9):531-534. DOI: 10.1007/s10330-011-0822-7


ObjectiveThe aim of our study was to evaluate the clinical efficacy and tolerability of metronomic chemotherapy in patients with advanced
ovarian carcinoma.

MethodsFifteen patients with advanced ovarian carcinoma and bad performance status were subjected to daily cyclophosphamide (CTX)
after failure of 1st line chemotherapy which included paclitaxel and carboplatin. Evaluation of the cases during treatment
as regard treatment side effects and progression free survival.

ResultsPatients could tolerate low dose oral cyclophosphamide treatment without considerable side effects with improvement of performance
status. The mean progression free survival was 12 months.

ConclusionLow dose oral cyclophosphamide could be considered as a palliative treatment of pretreated ovarian carcinomas with poor performance

Key wordsmetronomic–chemotherapy–ovarian carcinoma

13 Reads